Curesponse
PrivateLast Round
Series B
Nov 15, 2021
Total Funding Raised
$14M
Company Overview
Curesponse is a biotechnology company that has developed a cancer treatment testing platform designed to identify effective therapy for individual patients.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Medical AI, Drug Discovery, Clinical Trials, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Curesponse Comparables
Compare Curesponse with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| First Ascent Biomedical | 87% | |
| SageMedic Corp. | 87% | |
| Xilis | 82% | |
Curesponse Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 15, 2021 | ||||
| Series A | Jun 5, 2020 |
Curesponse Investors
Notable investors and investment history
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 5, 2025
Grew 20% QoQ from 15 to 18 employees.
- Apr 13, 2025
Monthly visitors grew 151% MoM, reaching 223.
Curesponse Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Curesponse's valuation, stock price, and market status.